Nicola Martucci

Dr. Nicola Martucci

Istituto Nazionale Tumori "Fondazione Pascale"
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2020 in Cancers
Verified
Journal Article
Open access
PDF file
GEGiovanna Esposito
Giovanna Esposito
GPGiuliano Palumbo
Giuliano Palumbo
Guido CarillioGuido Carillio
Guido Carillio
AMAnna Manzo
Anna Manzo
AMAgnese Montanino
Agnese Montanino
Alessandro MorabitoAlessandro Morabito
Alessandro Morabito
Small-cell lung cancer (SCLC) is an aggressive tumor type with limited therapeutic options and poor prognosis. Chemotherapy regimens containing platinum represent the cornerstone of treatment for patients with extensive disease, but there has been no real progress for 30 years. The evidence that SCLC is characterized by a high mutational burden led to the development of immune-checkpoint inhibitors as single agents or in combination with chemotherapy. Randomized phase III trials demonstrated that the combination of atezolizumab (IMpower-133) or durvalumab (CASPIAN) with platinum-etoposide chemotherapy improved overall survival of patients with extensive disease. Instead, the KEYNOTE-604 study demonstrated that the addition of pembrolizumab to chemotherapy failed to significantly improve overall survival, but it prolonged progression-free survival. The safety profile of these combinations was similar with the known safety profiles of all single agents and no new adverse events were observed. Nivolumab and pembrolizumab single agents showed anti-tumor activity and acceptable safety profile in Checkmate 032 and KEYNOTE 028/158 trials, respectively, in patients with SCLC after platinum-based therapy and at least one prior line of therapy. Future challenges are the identification predictive biomarkers of response to immunotherapy in SCLC and the definition of the role of immunotherapy in patients with limited stage SCLC, in combination with radiotherapy or with other biological agents.

21 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
NMNicola Martucci
Nicola Martucci
Alessandro MorabitoAlessandro Morabito
Alessandro Morabito
ARAntonello La Rocca
Antonello La Rocca
GLGiuseppe De Luca
Giuseppe De Luca
RCRossella De Cecio
Rossella De Cecio
CMCarmine La Manna
Carmine La Manna
Small-cell lung cancer (SCLC) is one of the most aggressive tumors, with a rapid growth and early metastases. Approximately 5% of SCLC patients present with early-stage disease (T1,2 N0M0): these patients have a better prognosis, with a 5-year survival up to 50%. Two randomized phase III studies conducted in the 1960s and the 1980s reported negative results with surgery in SCLC patients with early-stage disease and, thereafter, surgery has been largely discouraged. Instead, several subsequent prospective studies have demonstrated the feasibility of a multimodality approach including surgery before or after chemotherapy and followed in most studies by thoracic radiotherapy, with a 5-year survival probability of 36–63% for patients with completely resected stage I SCLC. These results were substantially confirmed by retrospective studies and by large, population-based studies, conducted in the last 40 years, showing the benefit of surgery, particularly lobectomy, in selected patients with early-stage SCLC. On these bases, the International Guidelines recommend a surgical approach in selected stage I SCLC patients, after adequate staging: in these cases, lobectomy with mediastinal lymphadenectomy is considered the standard approach. In all cases, surgery can be offered only as part of a multimodal treatment, which includes chemotherapy with or without radiotherapy and after a proper multidisciplinary evaluation.

17 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
AOAlessandro Ottaiano
Alessandro Ottaiano
MSMariachiara Santorsola
Mariachiara Santorsola
LCLuisa Circelli
Luisa Circelli
ATAnna Maria Trotta
Anna Maria Trotta
FIFrancesco Izzo
Francesco Izzo
Michele CaragliaMichele Caraglia
Michele Caraglia
Some cancer patients display a less aggressive form of metastatic disease, characterized by a low tumor burden and involving a smaller number of sites, which is referred to as “oligometastatic disease” (OMD). This review discusses new biomarkers, as well as methodological challenges and perspectives characterizing OMD. Recent studies have revealed that specific microRNA profiles, chromosome patterns, driver gene mutations (ERBB2, PBRM1, SETD2, KRAS, PIK3CA, SMAD4), polymorphisms (TCF7L2), and levels of immune cell infiltration into metastases, depending on the tumor type, are associated with an oligometastatic behavior. This suggests that OMD could be a distinct disease with specific biological and molecular characteristics. Therefore, the heterogeneity of initial tumor burden and inclusion of OMD patients in clinical trials pose a crucial methodological question that requires responses in the near future. Additionally, a solid understanding of the molecular and biological features of OMD will be necessary to support and complete the clinical staging systems, enabling a better distinction of metastatic behavior and tailored treatments.

31 July 2010 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
Gaetano RoccoGaetano Rocco
Gaetano Rocco
FFFlavio Fazioli
Flavio Fazioli
CMCarmine La Manna
Carmine La Manna
ARAntonello La Rocca
Antonello La Rocca
SMStefano Mori
Stefano Mori
RSRosario Salvi
Rosario Salvi

1 June 1997 in Clinical Drug Investigation
Verified
Journal Article
Closed access
PDF file
GNGiuseppe Nappi
Giuseppe Nappi
GBGiorgio Bono
Giorgio Bono
PMPaola Merlo
Paola Merlo
ABAlessandro Borromei
Alessandro Borromei
CCCarlo Caltagirone
Carlo Caltagirone
ABAngelo Battaglia
Angelo Battaglia

1 July 2011 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
Gaetano RoccoGaetano Rocco
Gaetano Rocco
LSLuca Serra
Luca Serra
FFFlavio Fazioli
Flavio Fazioli
SMStefano Mori
Stefano Mori
FMFarrokh Mehrabi-Kermani
Farrokh Mehrabi-Kermani
GAGaetano Apice
Gaetano Apice